The European Medicines Agency (EMA) gave the green light on Thursday 24 February to an extension of the use of Spikevax, the Covid-19 vaccine developed by the company Moderna, to children aged 6 to 11 years.
Spikevax already has a conditional marketing authorisation for use in people aged 12 and over.
In this case, the EMA recommends intramuscular administration in the arm at four week intervals. The vaccine dose is 50 µg and provides an immune response in 6 to 11-year-olds comparable...